Leading Pharma, LLC is recalling 2,952 bottles of Lorazepam Tablets (lorazepam) because the bottles are labeled as 0.5 mg strength but actually contain 1 mg tablets. This recall affects 500-count bottles of the prescription medication distributed nationwide across the United States. Consumers who take a 1 mg tablet instead of the prescribed 0.5 mg dose will receive double the intended medication, which can lead to excessive sedation or other adverse effects. You should contact your healthcare provider or pharmacist immediately if you believe you have the affected product.
Taking double the intended dose of lorazepam poses a significant risk of excessive central nervous system depression, which can cause extreme drowsiness, confusion, and impaired coordination. This labeling error increases the likelihood of accidental overdose, especially in patients who are sensitive to the medication or are taking other sedatives.
Pharmacy refund and healthcare guidance
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.